BiotechTube

Paclitaxel + CB-839

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer

Conditions

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer

Trial Timeline

May 1, 2017 → Nov 25, 2019

NCT ID
NCT03057600

About Paclitaxel + CB-839

Paclitaxel + CB-839 is a phase 2 stage product being developed by Calithera Biosciences for Triple Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03057600. Target conditions include Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer.

What happened to similar drugs?

1 of 20 similar drugs in Triple Negative Breast Cancer were approved

Approved (1) Terminated (1) Active (18)
✅Taxane and Carboplatin + Short-term SintilimabInnovent BiologicsApproved
🔄Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
🔄Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
🔄Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
🔄Sacituzumab Govitecan-hziy + Pembrolizumab + Paclitaxel + nab-Paclitaxel + Gemcitabine + CarboplatinMerckPhase 3
🔄Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
🔄pembrolizumab + capecitabine + eribulin + gemcitabine + vinorelbineMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03057600Phase 2Completed

Competing Products

20 competing products in Triple Negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
eFT508eFFECTOR TherapeuticsPhase 2
17
No drugDaiichi SankyoPre-clinical
30
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Abemaciclib + BicalutamideEli LillyPhase 2
42
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
34
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab + Nab paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
31
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
29
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
40
Combination of Veliparib + LapatinibAbbViePre-clinical
26
Capivasertib + ItraconazoleAstraZenecaPhase 1
29
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
42
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
36
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
29
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
44
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
35